The evolution of clinical diagnosis and treatment of castration-resistant prostate cancer from the updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
10.3760/cma.j.cn112330-20220818-00469
- VernacularTitle:从PCWG3共识的更新看去势抵抗性前列腺癌临床诊治的演变
- Author:
Xu GAO
1
Author Information
1. 海军军医大学第一附属医院泌尿外科，上海 200433
- Keywords:
Prostatic neoplasm;
Carcinoma;
Castration-resistant;
Non-metastatic;
Prostate Cancer Clinical Trials Working Group;
Prostate-specific antigen
- From:
Chinese Journal of Urology
2022;43(12):884-888
- CountryChina
- Language:Chinese
-
Abstract:
Castration-resistant prostate cancer (CRPC) is an important research focus in the field of prostate cancer. The adjustment of its diagnosis criteria also directly impacts the clinical diagnosis and treatment practice, as well as the design and implementation of the relevant clinical trials. The Prostate Cancer Clinical Trials Working Group (PCWG) has published several consensuses to provide further reference in clinical practice and trials design. In PCWG3, the recommended PSA cut-off value to confirmed CRPC diagnosis was further lowered from 2 ng / ml to 1 ng/ml. The update of PCWG3 may have a profound impact on the clinical diagnosis, treatment and trials design of prostate cancer in the future.
